H S Sader

Summary

Country: Brazil

Publications

  1. ncbi request reprint Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program
    H S Sader
    Special Laboratory of Clinical Microbiology, Division of Infectious Diseases, Federal University of Sao Paulo, SP, Brazil
    Braz J Infect Dis 5:200-14. 2001
  2. ncbi request reprint Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns
    Helio S Sader
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 44:281-8. 2002
  3. ncbi request reprint Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers
    Helio S Sader
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 44:273-80. 2002
  4. ncbi request reprint Antimicrobial activity of linezolid against Gram-positive cocci isolated in Brazil
    H S Sader
    Division of Infectious Diseases, Federal University of Sao Paulo, Sao Paulo, SP, Brazil
    Braz J Infect Dis 5:171-6. 2001
  5. ncbi request reprint Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents
    H S Sader
    Division of Infectious Diseases, Universidade Federal de Sao Paulo Escola Paulista de Medicina, Sao Paulo, Brazil
    Drugs 61:553-64. 2001
  6. ncbi request reprint Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study
    H S Sader
    Division of Infectious Diseases, Federal University of Sao Paulo, Rua Botucatu, 740, Sao Paulo SP, 04023 063 Brazil
    Braz J Infect Dis 5:21-31. 2001
  7. ncbi request reprint Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98)
    H S Sader
    Federal University of Sao Paulo, Medical School of Medecine, Sao Paulo, Sao Paulo, Brazil
    Braz J Infect Dis 4:245-54. 2000
  8. ncbi request reprint Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999
    A C Gales
    University of Iowa College of Medicine, Iowa City, Iowa, USA, and Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Clin Infect Dis 32:S104-13. 2001
  9. ncbi request reprint Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program
    A C Gales
    Universidade Federal de Sao Paulo, Division of Infectious Diseases, Department of Medicine, Sao Paulo, Brazil
    J Chemother 16:323-8. 2004
  10. ncbi request reprint Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam
    H S Sader
    Special Clinical Microbiology Laboratory, Department of Infectious and Parasitic Diseases, Universidade Federal de Sao Paulo, Brazil
    Braz J Infect Dis 4:22-8. 2000

Detail Information

Publications82

  1. ncbi request reprint Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program
    H S Sader
    Special Laboratory of Clinical Microbiology, Division of Infectious Diseases, Federal University of Sao Paulo, SP, Brazil
    Braz J Infect Dis 5:200-14. 2001
    ..Thus, regional surveillance programs are essential to guide empirical therapy and infection control measures...
  2. ncbi request reprint Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns
    Helio S Sader
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 44:281-8. 2002
    ..National and international surveillance programs as a guide to focusing intervention strategies should assist in the control of escalating antimicrobial resistance in this geographic area...
  3. ncbi request reprint Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers
    Helio S Sader
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 44:273-80. 2002
    ..In summary, resistance to most antimicrobial agents for a number of species implicated in bacteremia, especially among Gram-negative rods, has reached worrisome levels and continues to increase...
  4. ncbi request reprint Antimicrobial activity of linezolid against Gram-positive cocci isolated in Brazil
    H S Sader
    Division of Infectious Diseases, Federal University of Sao Paulo, Sao Paulo, SP, Brazil
    Braz J Infect Dis 5:171-6. 2001
    ..The excellent in vitro Gram-positive activity by linezolid, in this study, indicate that this compound may represent an important therapeutic option for the treatment of infections caused by these pathogens in Brazil...
  5. ncbi request reprint Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents
    H S Sader
    Division of Infectious Diseases, Universidade Federal de Sao Paulo Escola Paulista de Medicina, Sao Paulo, Brazil
    Drugs 61:553-64. 2001
    ..However, when compared with the parenterally administered compounds, the oral agents seem to lose some in vitro antibacterial activity, especially against P. aeruginosa...
  6. ncbi request reprint Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study
    H S Sader
    Division of Infectious Diseases, Federal University of Sao Paulo, Rua Botucatu, 740, Sao Paulo SP, 04023 063 Brazil
    Braz J Infect Dis 5:21-31. 2001
    ..These results define the role of quinupristin/dalfopristin in Latin American medical centers and provide a benchmark for future in vitro comparisons...
  7. ncbi request reprint Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98)
    H S Sader
    Federal University of Sao Paulo, Medical School of Medecine, Sao Paulo, Sao Paulo, Brazil
    Braz J Infect Dis 4:245-54. 2000
    ..The newer fluoroquinolones show an excellent potency and spectrum against pathogens causing community acquired respiratory infections in Latin America...
  8. ncbi request reprint Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999
    A C Gales
    University of Iowa College of Medicine, Iowa City, Iowa, USA, and Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Clin Infect Dis 32:S104-13. 2001
    ..maltophilia isolates observed in this study emphasize the importance of local surveillance in determining the most adequate therapy for acinetobacter and S. maltophilia infections and the possible clonal, epidemic nature of occurrence...
  9. ncbi request reprint Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program
    A C Gales
    Universidade Federal de Sao Paulo, Division of Infectious Diseases, Department of Medicine, Sao Paulo, Brazil
    J Chemother 16:323-8. 2004
    ..5%) and varied widely (10.0 to 48.9%) among the monitored Latin American medical centers. Mupirocin resistance rates appear to be increasing and routine monitoring for potential resistance seems prudent...
  10. ncbi request reprint Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam
    H S Sader
    Special Clinical Microbiology Laboratory, Department of Infectious and Parasitic Diseases, Universidade Federal de Sao Paulo, Brazil
    Braz J Infect Dis 4:22-8. 2000
    ..3% to 98.2% susceptibility). In sum, piperacillin/tazobactam was more active against all Gram-negative species than the other two combinations, with the exception of A. baumannii, and showed similar activity against Gram-positive cocci...
  11. ncbi request reprint In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitals
    A O Reis
    Division of Infectious Diseases, , Rua Botucatu 740, , SP 04023-063, Brazil
    Braz J Infect Dis 5:243-51. 2001
    ..faecium and E. faecalis among Brazilian hospitals. The results of this study indicate that linezolid is an appropriate therapeutic option for the treatment of vancomycin-resistant enterococci infections in Brazil...
  12. ncbi request reprint In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant Staphylococcus aureus isolated in Brazilian hospitals
    J C Cordeiro
    Special Clinical Microbiology Laboratory, Division of Infectious Diseases, , SP, Brazil
    Braz J Infect Dis 5:130-5. 2001
    ....
  13. ncbi request reprint Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002
    C Mendes
    Fleury Medical Diagnostic Centre, Sao Paulo, Brazil
    Clin Microbiol Infect 10:521-6. 2004
    ..Levofloxacin, a fluoroquinolone prescribed widely for respiratory tract infections, continued to show potent activity against key respiratory pathogens...
  14. ncbi request reprint IMPs, VIMs and SPMs: the diversity of metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital
    H S Sader
    Laboratorio Alerta e Laboratorio Especial de Microbiologia Clínica, Disciplina de Doencas Infecciosas e Parasitarias, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Clin Microbiol Infect 11:73-6. 2005
    ..MBL production was detected in 36 isolates (19.7% of the entire collection; 43.9% of the imipenem-resistant isolates) and the MBLs included SPM-1-like (55.6%), VIM-2-like (30.6%) and IMP-1-like (8.3%) enzymes...
  15. ncbi request reprint Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection
    A R Marra
    Universidade Federal de Sao Paulo, Escola Paulista de Medicina, Disciplina de Doencas Infecciosas e Parasitarias, Rua Botucatu, 743, 7 andar, Vila Clementino, CEP 04023 062, Sao Paulo, SP, Brazil
    Int J Infect Dis 10:56-60. 2006
    ..For hospitals with a high prevalence of strains producing this enzyme, there is no reference material to show whether the use of the E-test method for their detection, which can be quite expensive, is actually required...
  16. ncbi request reprint Screening of antibacterial extracts from plants native to the Brazilian Amazon Rain Forest and Atlantic Forest
    I B Suffredini
    Laboratório de Extração, Universidade Paulista, Sao Paulo, SP, Brasil
    Braz J Med Biol Res 37:379-84. 2004
    ..The most active fractions are being fractionated to identify their active substances. Higher concentrations of other extracts are currently being evaluated against the same microorganisms...
  17. ncbi request reprint Epidemiologic typing of multiply drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unit
    H S Sader
    Department of Infectious Disease, Paulist School of Medicine, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 17:13-8. 1993
    ..The chrDNA fingerprinting proved to be versatile and precise for epidemiologic investigations of P. aeruginosa infections...
  18. pmc Heterogeneity of Pseudomonas aeruginosa in Brazilian cystic fibrosis patients
    S Silbert
    Laboratório Especial de Microbiologia Clínica, Disciplina de Doencas Infecciosas e Parasitarias, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    J Clin Microbiol 39:3976-81. 2001
    ..aeruginosa for long periods of time. In addition, the finding of several different genotypes in the same patient suggests that the colonizing strain may occasionally be replaced...
  19. ncbi request reprint Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres
    A C Gales
    Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Clin Microbiol Infect 11:95-100. 2005
    ..and Listeria spp. Dalbavancin may provide an important therapeutic option for Gram-positive infections, excluding those caused by enterococci with VanA-type resistance...
  20. ncbi request reprint Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)
    A C Gales
    Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Clin Microbiol Infect 12:315-21. 2006
    ..4% susceptible), and was very limited (MIC50, > 8 mg/L) against Burkholderia cepacia (11.8% susceptible), Serratia spp. (5.4% susceptible), indole-positive Proteus spp. (1.3% susceptible) and Proteus mirabilis (0.7% susceptible)...
  21. ncbi request reprint Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
    A C Galles
    Laboratório ALERTA, Universidade Federal de Sao Paulo, Brazil
    J Chemother 20:38-42. 2008
    ..5% susceptible by published breakpoint criteria) and moxifloxacin (MIC(90), 2 micro g/ml) MIC results was observed indicating that moxifloxacin could be further evaluated as a therapeutic option for S. maltophilia infections...
  22. ncbi request reprint In vitro activity of ampicillin-sulbactam against clinical multiresistant Acinetobacter baumannii isolates
    A C Gales
    Division of Infectious Diseases, , Escola Paulista de Medicina, Brazil
    J Chemother 8:416-9. 1996
    ..baumannii; however, further studies are necessary to evaluate the clinical role of this compound for the treatment of severe infections...
  23. ncbi request reprint Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 55:351-6. 2006
    ..Cefdinir should be considered as a viable option for the therapy uSSTI caused by indicated species...
  24. ncbi request reprint Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)
    Paul R Rhomberg
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 56:57-62. 2006
    ....
  25. ncbi request reprint Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004)
    Amy A Watters
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 57:914-23. 2006
    ....
  26. ncbi request reprint Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003)
    Kelley A Fedler
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 55:157-64. 2006
    ..pneumoniae (refractory otitis media) and P. aeruginosa (cystic fibrosis associated pneumonia)...
  27. ncbi request reprint Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)
    Michael A Pfaller
    Department of Pathology and Epidemiology, University of Iowa College of Medicine and College of Public Health, Iowa City, IA 52242, USA
    Diagn Microbiol Infect Dis 56:63-8. 2006
    ..isolated in North American medical centers. Continued resistances surveillance monitoring will be necessary to assess the effectiveness of widely used broad-spectrum antimicrobials as novel resistance mechanisms emerge...
  28. ncbi request reprint Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 54:149-53. 2006
    ..Dalbavancin wild-type MIC distributions remain unchanged compared with prior sampled years (2002-2003) in the USA...
  29. ncbi request reprint Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002)
    Ana C Gales
    Departamento de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, SP 04025 010, Brasil
    Mem Inst Oswaldo Cruz 100:571-7. 2005
    ..Since selection of the most appropriate antimicrobial agents for testing and reporting has not been established by the NCCLS for many of NF-GNB species, results from large multicenter studies may help to guide the best empiric therapy...
  30. ncbi request reprint Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests
    Ronald N Jones
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 56:1047-52. 2005
    ..To evaluate bactericidal activity of PPI-0903M and in vitro testing parameters for this compound...
  31. ncbi request reprint Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:265-73. 2005
    ..Continued resistance surveillance is critical to monitor the effectiveness of widely used parenteral antimicrobial agents such as cefepime...
  32. ncbi request reprint Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:203-8. 2005
    ..aeruginosa) isolated from ICU patients and may represent an excellent option for the treatment of infections in this clinical environment...
  33. pmc Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program
    Ronald N Jones
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Clin Microbiol 44:2622-5. 2006
    ..Vancomycin test results most reliably predict dalbavancin susceptibility until validated commercial reagents become available for direct testing in clinical practice...
  34. ncbi request reprint Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)
    Ronald N Jones
    JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 57:109-16. 2007
    ..4% and 2.3%, respectively). Our results indicate that cefepime was the most broad-spectrum cephalosporin analyzed and remains a very potent alternative for the treatment of contemporary pediatric infections in North America...
  35. ncbi request reprint Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines?
    Soraya S Andrade
    Laboratório Especial de Microbiologia Clínica, Universidade Federal de Sao Paulo, 04025 010 São Paulo, SP, Brazil
    Mem Inst Oswaldo Cruz 101:741-8. 2006
    ..Our results highlight the need for developing specific CA-UTI guidelines in geographic regions where elevated resistance to new and old compounds may influence prescribing decisions...
  36. doi request reprint Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 61:1092-8. 2008
    ..We evaluated the spectrum and potency of omiganan against pathogens commonly associated with such infections...
  37. ncbi request reprint Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 59:467-72. 2007
    ....
  38. ncbi request reprint Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 30:514-20. 2007
    ..1%) and imipenem in Spain (87.7%). Our results suggest that tigecycline represents a viable additional option for the empirical treatment of cSSSI in these countries...
  39. pmc Detection of inducible clindamycin resistance in staphylococci by broth microdilution using erythromycin-clindamycin combination wells
    Jana M Swenson
    Antimicrobial Resistance Team, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Clin Microbiol 45:3954-7. 2007
    ..After a 24-h incubation, the ERY-CC combinations of 4 and 0.5, 6 and 1, and 8 and 1.5 microg/ml correlated well with the D-zone test...
  40. ncbi request reprint Evaluation of the susceptibility profiles, genetic similarity and presence of qnr gene in Escherichia coli resistant to ciprofloxacin isolated in Brazilian hospitals
    Andrea S Pereira
    Special Laboratory of Microbiology, Federal University of Sao Paulo, SP, Brazil
    Braz J Infect Dis 11:40-3. 2007
    ..The great genomic variability found among the ciprofloxacin-resistant Escherichia coli highlights the importance of the appropriate use of quinolone to restrict the selection of resistant isolates...
  41. pmc Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of view
    Daniel Curcio
    J Clin Microbiol 45:2095; author reply 2095-6. 2007
  42. pmc Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital
    Rodrigo E Mendes
    Laboratório Especial de Microbiologia Clínica and Laboratório ALERTA, Division of Infectious Disease, Federal University of Sao Paulo, Sao Paulo, Brazil
    Antimicrob Agents Chemother 51:2611-4. 2007
    ..This report describes the ability of nonfermentative nosocomial pathogens to acquire and disseminate antimicrobial resistance determinants...
  43. pmc Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    BMC Infect Dis 7:29. 2007
    ..We evaluated the in vitro activity of this compound and selected comparator agents tested against clinical strains of staphylococci and enterococci collected in European medical centers in 2005...
  44. ncbi request reprint In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 58:27-32. 2007
    ....
  45. ncbi request reprint Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004)
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 58:19-26. 2007
    ..These in vitro data suggest that garenoxacin warrants further clinical studies in SSTI, especially against staphylococci and streptococcal pathogens...
  46. ncbi request reprint Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005)
    Michael A Pfaller
    University of Iowa, Iowa City, IA 52242, USA
    Diagn Microbiol Infect Dis 57:459-65. 2007
    ..5, and 1 microg/mL for staphylococci, enterococci, beta-hemolytic streptococci, and viridans group streptococci, respectively, and no significant loss in potency was observed over the period studied...
  47. ncbi request reprint Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study
    James E Ross
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 29:295-301. 2007
    ..With MDR in Gram-positive organisms increasing in prevalence, continued surveillance of linezolid appears to be prudent practice as linezolid becomes more widely prescribed for these difficult-to-treat infections...
  48. ncbi request reprint Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004)
    Lalitagauri M Deshpande
    JMI Laboratories, North Liberty, Iowa, USA
    Microb Drug Resist 12:223-30. 2006
    ....
  49. pmc Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
    Douglas J Biedenbach
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Clin Microbiol 45:998-1004. 2007
    ..Dalbavancin demonstrated excellent potency and activity (100% susceptibility at proposed breakpoints) against common causes of SSSI pathogens in this U.S. multicenter study sample...
  50. doi request reprint Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006)
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 61:86-95. 2008
    ..These characteristics warrant continued evaluation of the agent as empiric therapy for cSSSIs, and in pneumonia, especially in those institutions/regions where MRSA and P. aeruginosa may be prevalent...
  51. ncbi request reprint Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004)
    Thomas R Fritsche
    JMI Laboratories, Inc, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:195-201. 2005
    ..Tigecycline represents a new choice among broad-spectrum parenteral agents for the common Gram-positive and -negative pathogens producing serious infections of skin and soft tissues...
  52. ncbi request reprint Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:187-93. 2005
    ..Further clinical studies should consider the role that tigecycline may play in the therapy for severe respiratory tract infections, both of nosocomial and community origin...
  53. ncbi request reprint Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations
    Ronald N Jones
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 54:144-54. 2004
    ..To investigate the potency of doripenem, a broad-spectrum carbapenem characterized by a wider spectrum of activity combining antimicrobial and bactericidal features of imipenem and meropenem...
  54. ncbi request reprint Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates
    Ronald N Jones
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 53:804-7. 2004
    ..To evaluate the potency of a novel peptide deformylase inhibitor, NVP PDF-713, against Gram-positive organisms having resistances to linezolid or quinupristin/dalfopristin...
  55. ncbi request reprint Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms
    Jennifer M Streit
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    J Antimicrob Chemother 53:669-74. 2004
    ..Increasing antimicrobial resistance among bacterial pathogens has prompted attempts to develop new antimicrobial agents active against multidrug-resistant Gram-positive pathogens...
  56. ncbi request reprint Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates
    Jennifer M Streit
    The JONES Group JMI Laboxratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 48:137-43. 2004
    ..Some VRE were inhibited by very low dalbavancin concentrations (< or = 1 microg/ml; Van B phenotypes). Further clinical development seems warranted for this once-weekly administered agent...
  57. ncbi request reprint Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres
    Paul R Rhomberg
    The JONES Group, JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 23:52-9. 2004
    ..Most apparent were the decreasing susceptibility rates for ciprofloxacin and ceftazidime against staphylococci. Continued surveillance in these institutions appears warranted as sites of high potential emerging resistance risk...
  58. ncbi request reprint Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001)
    Alan H Mutnick
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 53:290-6. 2004
    ..The current report evaluates these relationships for Enterobacteriaceae and Pseudomonas aeruginosa over the initial 3 year period of the programme in the USA...
  59. pmc In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 48:53-62. 2004
    ..In conclusion, LB 11058 demonstrated a broad antibacterial spectrum and was highly active against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci...
  60. ncbi request reprint Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001)
    Ronald N Jones
    The JONES Group JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 22:551-6. 2003
    ..Resistance surveillance among these organisms remains necessary to guide empirical antimicrobial therapy, especially for these less frequently isolated and difficult to test pathogens...
  61. ncbi request reprint The use of molecular typing to evaluate the dissemination of antimicrobial resistance among Gram-negative rods in Brazilian hospitals
    Iraci Tosin
    Federal University of Sao Paulo, Special Laboratory of Clinical Microbiology, Florianápolis, SC, Brazil
    Braz J Infect Dis 7:360-9. 2003
    ..We conclude that the ability to characterize organisms phenotypically and genotypically is a powerful epidemiologic tool and it provides unique information that is very important for multicenter surveillance programs...
  62. ncbi request reprint Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 47:547-50. 2003
    ....
  63. ncbi request reprint Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America:
    Thomas R Fritsche
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 47:435-40. 2003
    ..These findings confirm that the newer cephalosporins (cefepime and ceftriaxone) among broad-spectrum beta-lactam agents have a spectrum of activity that remains comprehensive for the commonly isolated Gram-positive pathogens...
  64. ncbi request reprint Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States
    Kelley A Gordon
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 47:377-83. 2003
    ..03 microg/ml) and Legionella spp. (MIC(90), 0.5 microg/ml). These results on recently isolated organisms indicate that grepafloxacin has a sustained potency and spectrum against most clinically important and indicated pathogens...
  65. ncbi request reprint Salmonella spp. isolates causing bloodstream infections in Latin America: report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000)
    Ana C Gales
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil
    Diagn Microbiol Infect Dis 44:313-8. 2002
    ....
  66. pmc Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity
    Helio S Sader
    The JONES Group JMI Laboratories, Inc, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 48:3112-8. 2004
    ..Kill curve experiments showed a clear pattern of bactericidal activity...
  67. ncbi request reprint SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001
    Helio S Sader
    Special Laboratory of Clinical Microbiology, Division of Infectious Diseases, Federal University of Sao Paulo, Sao Paulo, SP, Brazil
    Braz J Infect Dis 8:25-79. 2004
    ..This report allows the evaluation of the activities numerous antimicrobial agents against clinical isolates collected in Latin American countries...
  68. ncbi request reprint Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)
    Jennifer M Streit
    The JONES Group JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IW 52317, USA
    Int J Antimicrob Agents 24:111-8. 2004
    ..Cefepime and the carbapenems (imipenem or meropenem) for Gram-negative isolates and linezolid for Gram-positive isolates, provided the broadest spectrum of in vitro activity against contemporary ICU pathogens in North America...
  69. ncbi request reprint Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:181-6. 2005
    ..Serious infections in nosocomial environments should benefit from tigecycline use among the investigational phase 3 agents focused toward resistant strains...
  70. pmc Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains
    Helio S Sader
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 49:3501-12. 2005
    ....
  71. ncbi request reprint Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens
    Jennifer M Streit
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 53:307-10. 2005
    ..In summary, dalbavancin was very active against a wide spectrum of resistant Gram-positive isolates and demonstrated greater potency than vancomycin or teicoplanin...
  72. ncbi request reprint Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:71-4. 2005
    ..016 mug/mL (with higher values for ertapenem). Doripenem appears to be a promising, potent carbapenem for parenteral use against contemporary Gram-negative bacilli producing various beta-lactamases...
  73. pmc Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance
    Thomas R Fritsche
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 49:1468-76. 2005
    ....
  74. ncbi request reprint Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents
    Sudha Pottumarthy
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 25:282-9. 2005
    ..4%). Local and global surveillance studies of common respiratory pathogens such as S. pneumoniae remain instrumental to guide clinicians in appropriate empirical treatments and to emphasize the need for prudent antimicrobial use...
  75. ncbi request reprint Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels
    James E Ross
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 51:219-21. 2005
    ..0%) for on-scale results analyzed at +/-1 log2 dilution for same- and between-day comparisons. Newer and investigational fluoroquinolone agents, including gemifloxacin, can be tested with confidence using these dry-form MIC panels...
  76. ncbi request reprint Emerging epidemic of metallo-beta-lactamase-mediated resistances
    Ronald N Jones
    Diagn Microbiol Infect Dis 51:77-84. 2005
  77. ncbi request reprint Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli
    Helio S Sader
    JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 25:95-109. 2005
    ....
  78. ncbi request reprint Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program
    Helio S Sader
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA, USA
    Int J Antimicrob Agents 25:57-61. 2005
    ..The emergence and dissemination of mobile MbetaL-producing isolates represent an alarming factor for increasing resistance to carbapenems in several medical centres evaluated by the SENTRY Program in Latin America...
  79. ncbi request reprint Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates
    Lalitagauri Deshpande
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 50:73-5. 2004
    ..BAL9141 displayed a predominant bactericidal activity against the majority of Gram-positive and -negative species, including resistant subsets, making it an attractive candidate for further development...
  80. ncbi request reprint Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:283-7. 2004
    ..Only 0.5% of all 415 recent CA-SSTI pathogens were resistant to cefdinir (MIC, > or = 4 mg/L). Cefdinir showed a spectrum and potency comparable or superior to other orally administered beta-lactams (cephalexin)...
  81. ncbi request reprint Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003)
    Paul R Rhomberg
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:273-81. 2004
    ..and Acinetobacter baumannii isolates. Continued surveillance of the carbapenem class and other broad-spectrum agents is warranted to monitor activity against pathogens causing serious infections in hospitalized patients...
  82. ncbi request reprint Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000)
    Ana C Gales
    Division of Infectious Diseases, Universidade Federal de, Sao Paulo, SP, Brazil
    Diagn Microbiol Infect Dis 44:289-99. 2002
    ..Carbapenem-resistant P. aeruginosa, ciprofloxacin-resistant E. coli, ESBL-producing K. pneumoniae constitute serious problem in this geographic region...